|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Arena Pharmaceuticals Inc., of San Diego, said data from a Phase Ia single-dose trial of its obesity compound, APD356, showed evidence of a pharmacologic effect on food intake with a 10-mg dose. APD356 also was shown to have a half-life of about 11 hours, which could support once-daily dosing. Food did not affect the absorption of APD356, which is an orally administered small molecule that is a selective 5-HT2C serotonin receptor agonist.
o Artemis Pharmaceuticals GmbH, of Cologne, Germany, and Evotec Neurosciences GmbH, of Hamburg, Germany, signed an agreement in mouse genetics. As part of the cooperation, Artemis will apply its ArteMice technology platforms ...